JP6652781B2 - 心血管系リスクイベントの予測およびその使用 - Google Patents

心血管系リスクイベントの予測およびその使用 Download PDF

Info

Publication number
JP6652781B2
JP6652781B2 JP2014533428A JP2014533428A JP6652781B2 JP 6652781 B2 JP6652781 B2 JP 6652781B2 JP 2014533428 A JP2014533428 A JP 2014533428A JP 2014533428 A JP2014533428 A JP 2014533428A JP 6652781 B2 JP6652781 B2 JP 6652781B2
Authority
JP
Japan
Prior art keywords
individual
risk
biomarkers
biomarker
event
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014533428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528576A (ja
JP2014528576A5 (enExample
Inventor
ギル，ロザリン・ダイアン
ウィリアムズ，ステファン・アラリック
スチュアート，アレックス・エイ．イー．
メーラー，ロバート
フォアマン，トルーディ
シンガー，ブリッタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SomaLogic Inc
Original Assignee
SomaLogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SomaLogic Inc filed Critical SomaLogic Inc
Publication of JP2014528576A publication Critical patent/JP2014528576A/ja
Publication of JP2014528576A5 publication Critical patent/JP2014528576A5/ja
Priority to JP2019193933A priority Critical patent/JP6917432B2/ja
Application granted granted Critical
Publication of JP6652781B2 publication Critical patent/JP6652781B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2014533428A 2011-09-30 2012-09-28 心血管系リスクイベントの予測およびその使用 Active JP6652781B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019193933A JP6917432B2 (ja) 2011-09-30 2019-10-25 心血管系リスクイベントの予測およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30
US61/541,828 2011-09-30
PCT/US2012/058060 WO2013049674A1 (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018103211A Division JP6546318B2 (ja) 2011-09-30 2018-05-30 心血管系リスクイベントの予測およびその使用
JP2019193933A Division JP6917432B2 (ja) 2011-09-30 2019-10-25 心血管系リスクイベントの予測およびその使用

Publications (3)

Publication Number Publication Date
JP2014528576A JP2014528576A (ja) 2014-10-27
JP2014528576A5 JP2014528576A5 (enExample) 2015-11-12
JP6652781B2 true JP6652781B2 (ja) 2020-02-26

Family

ID=47993164

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014533428A Active JP6652781B2 (ja) 2011-09-30 2012-09-28 心血管系リスクイベントの予測およびその使用
JP2018103211A Active JP6546318B2 (ja) 2011-09-30 2018-05-30 心血管系リスクイベントの予測およびその使用
JP2019193933A Active JP6917432B2 (ja) 2011-09-30 2019-10-25 心血管系リスクイベントの予測およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018103211A Active JP6546318B2 (ja) 2011-09-30 2018-05-30 心血管系リスクイベントの予測およびその使用
JP2019193933A Active JP6917432B2 (ja) 2011-09-30 2019-10-25 心血管系リスクイベントの予測およびその使用

Country Status (16)

Country Link
US (3) US20130085079A1 (enExample)
EP (1) EP2761289B1 (enExample)
JP (3) JP6652781B2 (enExample)
KR (2) KR102248900B1 (enExample)
CN (4) CN107102151A (enExample)
AU (1) AU2013202112B9 (enExample)
BR (2) BR122019023720B1 (enExample)
CA (2) CA2847903C (enExample)
ES (1) ES2777002T3 (enExample)
IL (1) IL231387A (enExample)
IN (1) IN2014CN01970A (enExample)
MX (2) MX373248B (enExample)
RU (1) RU2651708C2 (enExample)
SG (3) SG10201906900QA (enExample)
WO (1) WO2013049674A1 (enExample)
ZA (1) ZA201401778B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP6055966B2 (ja) * 2010-06-07 2017-01-11 マイクロ‐シグネチャー リミテッド 検出方法
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
MX350533B (es) 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
WO2012122540A1 (en) 2011-03-10 2012-09-13 Somalogic, Inc. Aptamers for clostridium difficile diagnostics
KR102248900B1 (ko) * 2011-09-30 2021-05-07 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
EP3584327A1 (en) 2012-01-27 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
MX361451B (es) 2013-09-24 2018-12-06 Somalogic Inc Detección objetivo de múltiples aptámeros.
CN110161252B (zh) * 2014-03-21 2022-10-14 赛诺菲-安万特德国有限公司 用于评估心血管病症进展风险的新标志物
WO2015185672A2 (en) * 2014-06-05 2015-12-10 Sanofi New markers for the assessment of an increased risk for mortality
BR112017005730B1 (pt) * 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
GB2556004A (en) * 2015-07-10 2018-05-16 Univ West Virginia Markers of stroke and stroke severity
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
US20210215711A1 (en) 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
WO2017156310A1 (en) * 2016-03-09 2017-09-14 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
EP3440468B1 (en) * 2016-04-06 2021-12-01 Nestle Sa BIOMARKER FOR PREDICTING THE DEGREE OF WEIGHT LOSS
EP3427650B1 (en) 2016-04-15 2021-06-23 Omron Corporation Biological information analyzing device, system, and program
CN105907857A (zh) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 一种用于动脉血栓的分子标记物和试剂及其应用
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
ES2817087T3 (es) * 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
SG11202003588QA (en) 2017-09-20 2020-05-28 Molecular Stethoscope Inc Methods and systems for detecting tissue conditions
US11942219B1 (en) * 2017-09-25 2024-03-26 Cerner Innovation, Inc. Determining a cardiovascular ischemic event and decision support tool
BR112020011454A2 (pt) * 2017-12-13 2021-02-09 F. Hoffmann-La Roche Ag métodos para prever o risco de acidente vascular, para prever o risco de acidente vascular cerebral e para aprimorar a precisão da previsão e usos do (i) biomarcador ang-2 e/ou do biomarcador igfbp7
RU2685859C1 (ru) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития ишемического инсульта
CN109192250B (zh) * 2018-08-01 2021-12-07 华东理工大学 一种多相催化中克服表面物种快速迁移的加速模拟方法
WO2020030803A1 (en) * 2018-08-10 2020-02-13 F. Hoffmann-La Roche Ag Ces-2 (carboxylesterase-2) for the assessment of afib related stroke
WO2020037244A1 (en) * 2018-08-17 2020-02-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
WO2020039001A1 (en) * 2018-08-22 2020-02-27 Roche Diagnostics Gmbh Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
EP3874275B1 (en) * 2018-10-31 2022-11-23 Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) Biomarkers of subclinical atherosclerosis
KR102125053B1 (ko) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트
GB2615975B (en) 2019-02-14 2023-11-29 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
EP4025916A1 (en) * 2019-09-03 2022-07-13 SomaLogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
US12699104B2 (en) * 2019-11-06 2026-08-04 National University Corporation Kagawa University Heart failure marker
US20230170050A1 (en) * 2020-04-17 2023-06-01 Phenomic Ai System and method for profiling antibodies with high-content screening (hcs)
US10902955B1 (en) 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
EP4153995A4 (en) * 2020-05-19 2024-10-23 Falcon Bioscience, LLC DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION ENGAGEMENT
FI130424B (en) * 2020-06-18 2023-08-23 Nightingale Health Oy Procedure for determining whether a subject has a disease or condition or whether the subject is at risk of developing a disease or condition
CA3195924A1 (en) * 2020-10-20 2022-04-28 Laura Mae SAMPSON Cardiovascular event risk prediction
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
US20240060998A1 (en) * 2021-02-01 2024-02-22 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
EP4399723A4 (en) * 2021-08-26 2024-10-02 3P Healthcare Pty Ltd SYSTEM AND METHODS FOR ASSESSMENT OF CARDIOVASCULAR HEALTH AND RISK MANAGEMENT
US12412661B2 (en) 2021-11-25 2025-09-09 Samsung Electronics Co., Ltd. Electronic device and method of providing health guideline using the same
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
CN114350670B (zh) * 2022-03-18 2022-06-14 北京市心肺血管疾病研究所 特异性识别可溶性st2蛋白的核酸适配体及其应用
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification
CN115932276B (zh) * 2022-12-07 2025-09-02 首都医科大学附属北京安贞医院 一种检测生物标志物的产品在制备急性心肌梗死或其并发症的诊断的产品中用途
WO2024226519A2 (en) * 2023-04-24 2024-10-31 Google Llc Deep learning-based photoplethysmography model for cardiovascular risk prediction
WO2026017134A1 (en) * 2024-07-19 2026-01-22 The University Of Hong Kong Methods and systems to determine early acute ischemic stroke (es) in acute ischemic stroke (ais) patients

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
ES2375181T3 (es) * 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
AU2005313938A1 (en) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Serum amyloid a protein in inflammation and obesity
CN2783324Y (zh) * 2005-04-28 2006-05-24 穆海东 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US20090226420A1 (en) * 2005-11-10 2009-09-10 Elizabeth Hauser Methods of Determining the Risk of Developing Coronary Artery Disease
ES2373989T3 (es) * 2006-01-31 2012-02-10 Mitsubishi Chemical Medience Corporation Procedimiento para la determinación del estado de un síndrome de coagulación intravascular diseminada.
EP2005168A4 (en) * 2006-03-09 2009-05-20 Biosite Inc METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
JP2011510297A (ja) * 2008-01-18 2011-03-31 バトリックス・メディカル・インコーポレイテッド 動脈瘤のための診断バイオマーカー
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
JP2012500199A (ja) * 2008-08-11 2012-01-05 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 血管統合性を促進するマイクロ−ｒｎａおよびその使用
ES2795003T3 (es) * 2008-10-07 2020-11-20 Brahms Gmbh Biomarcador para la predicción de los primeros eventos adversos
WO2010144358A1 (en) * 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
DK2443449T3 (en) * 2009-06-15 2017-05-15 Cardiodx Inc DETERMINATION OF RISK OF CORONARY ARTERY DISEASE
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
AU2010328019A1 (en) * 2009-12-09 2012-06-28 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
WO2011109642A1 (en) * 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
KR102248900B1 (ko) * 2011-09-30 2021-05-07 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
WO2013142114A1 (en) * 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure

Also Published As

Publication number Publication date
CN103959060B (zh) 2017-05-17
CN107422126A (zh) 2017-12-01
KR102111624B1 (ko) 2020-05-18
KR102248900B1 (ko) 2021-05-07
BR122019023720A2 (enExample) 2017-04-04
JP2014528576A (ja) 2014-10-27
BR112014007214A2 (pt) 2017-04-04
ZA201401778B (en) 2018-08-25
RU2014110508A (ru) 2015-11-10
MX2020004617A (es) 2020-08-06
ES2777002T3 (es) 2020-08-03
AU2013202112A1 (en) 2013-05-02
SG10201906900QA (en) 2019-09-27
HK1247666A1 (zh) 2018-09-28
IL231387A0 (en) 2014-04-30
CN114518458A (zh) 2022-05-20
MX2014003153A (es) 2014-04-30
US20130085079A1 (en) 2013-04-04
WO2013049674A1 (en) 2013-04-04
CN103959060A (zh) 2014-07-30
US20200166523A1 (en) 2020-05-28
US20150168423A1 (en) 2015-06-18
CN107102151A (zh) 2017-08-29
CA3074279A1 (en) 2013-04-04
IL231387A (en) 2017-12-31
JP2020024216A (ja) 2020-02-13
RU2651708C2 (ru) 2018-04-23
AU2013202112B9 (en) 2015-10-22
MX373248B (es) 2020-05-11
SG10201607331WA (en) 2016-11-29
NZ622118A (en) 2016-01-29
JP6917432B2 (ja) 2021-08-11
JP6546318B2 (ja) 2019-07-17
EP2761289B1 (en) 2020-02-12
BR122019023720A8 (pt) 2022-07-26
IN2014CN01970A (enExample) 2015-05-29
JP2018159713A (ja) 2018-10-11
BR122019023720B1 (pt) 2023-01-24
BR112014007214B1 (pt) 2022-08-16
CA2847903C (en) 2020-10-27
KR20140084106A (ko) 2014-07-04
KR20200055804A (ko) 2020-05-21
BR112014007214A8 (pt) 2022-07-26
CA3074279C (en) 2021-10-19
EP2761289A4 (en) 2015-08-12
CA2847903A1 (en) 2013-04-04
CN107422126B (zh) 2020-03-27
EP2761289A1 (en) 2014-08-06
AU2013202112B2 (en) 2015-09-24
SG11201400904SA (en) 2014-04-28

Similar Documents

Publication Publication Date Title
JP6917432B2 (ja) 心血管系リスクイベントの予測およびその使用
JP7270696B2 (ja) 心血管系のリスクイベントの予測及びその使用
AU2020343243A1 (en) Cardiovascular risk event prediction and uses thereof
HK40073398A (en) Cardiovascular risk event prediction and uses thereof
AU2015249162B2 (en) Cardiovascular risk event prediction and uses thereof
WO2026072744A2 (en) Methods of assessing hypertrophic cardiomyopathy
HK1236619A1 (en) Cardiovascular risk event prediction and uses thereof
HK1247666B (en) Cardiovascular risk event prediction and uses thereof
AU2021364805A1 (en) Cardiovascular event risk prediction
NZ622118B2 (en) Cardiovascular risk event prediction and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180530

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180619

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190917

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200124

R150 Certificate of patent or registration of utility model

Ref document number: 6652781

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250